Dapagliflozin prevents fibrogenic activation in endocardial endothelial cells under altered flow

Back

ESC Professional Premium Access

Dapagliflozin prevents fibrogenic activation in endocardial endothelial cells under altered flow

Session: Adult congenital heart disease: medical treatment

Topic: Pharmacotherapy

Speaker: Ms J. Gaal (Boston, US) Doctor I. Friehs (Boston, US)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speakers

Ms Julia Gaal

Boston Children's Hospital, Boston (United States of America)

0 follower

Doctor Ingeborg Friehs

Boston Children's Hospital, Boston (United States of America)

1 presentation

0 follower

8 more presentations in this session

Sodium-glucose cotransporter 2 inhibitors for the treatment of single ventricle circulatory failure in adults with congenital heart disease

Speaker: Doctor R. Neijenhuis (Leiden, NL)

Access

Abstract

Video

Results of CHASM IN ACHD (peer CoacHing Adaptive Self-Management INterventions for young Adults with Congenital Heart Disease) study

Speaker: Doctor R. Krasuski (Durham, US)

Access

Abstract

Video

Sacubitril/ valsartan in patients with congenital heart disease: a systematic review and meta-analysis

Speaker: Doctor D. Ntiloudi (Pireas, GR)

Access

Abstract

Video

Sodium-glucose cotransporter-2 inhibitor use in children with left ventricular systolic dysfunction: a matched case-control analysis

Speaker: Doctor D. Newland (Seattle, US)

Access

Abstract

Video

Impact on adverse events of guideline-directed medical therapy for heart failure in patients with a systemic right ventricle

Speaker: Doctor I. Altobelli (Naples, IT)

Access

Abstract

Video

Access the full session

Adult congenital heart disease: medical treatment

Speakers: Ms J. Gaal, Doctor I. Friehs, Doctor R. Neijenhuis, Doctor R. Krasuski, Doctor D. Ntiloudi...

Access

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources